TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
SAN DIEGO, December 01, 2008 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.
Details of the presentation are as follows: Title: A Phase I Study of TG101348, an Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis Presenter: Dr. Animesh Pardanani, Mayo Clinic Session Name: Myeloproliferative Disorders-Experimental Therapeutics Session Date: Sunday, December 7, 2008 Presentation Time: 4:30 PM Room: Moscone Center SOUTH, Rooms 304-306-308 Directions: Howard Street entrance, turn left, up 2 flights of stairs to Esplanade level
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.
CONTACT: TargeGen, Inc., +1-858-678-0760, fax, +1-858-678-0160, email@example.com
Web site: http://www.targegen.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2008